
LWT, Год журнала: 2024, Номер unknown, С. 117191 - 117191
Опубликована: Дек. 1, 2024
Язык: Английский
LWT, Год журнала: 2024, Номер unknown, С. 117191 - 117191
Опубликована: Дек. 1, 2024
Язык: Английский
Computational Biology and Chemistry, Год журнала: 2025, Номер 117, С. 108390 - 108390
Опубликована: Фев. 22, 2025
Язык: Английский
Процитировано
1Steroids, Год журнала: 2025, Номер unknown, С. 109601 - 109601
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0The American Journal of Chinese Medicine, Год журнала: 2025, Номер unknown, С. 1 - 23
Опубликована: Март 27, 2025
Non-small cell lung cancer (NSCLC) is a malignancy that faces serious resistance challenges in treatment. In this study, we identified Piperlongumine as promising therapeutic candidate to overcome Osimertinib NSCLC. We systematically investigated the inhibitory effect of on NSCLC cells and confirmed it could effectively inhibit vitro kinase activity wild-type (WT), exon 19 deletion, L858R/T790M-mutated EGFR. also found Piperlongumine-induced intrinsic apoptosis by interfering with EGFR signaling pathway, which was characterized down-regulation anti-apoptotic protein Mcl-1. Further mechanistic studies revealed degradation Mcl-1 dependent Akt-GSK3[Formula: see text] pathway. Additionally, Piperlongumine-promoted interaction between [Formula: text]-TRCP, thereby enhancing text]-TRCP-mediated ubiquitination Furthermore, significantly inhibited tumor growth both Osimertinib-sensitive resistant xenograft models. These findings highlight potential an effective agent overcoming EGFR-targeted therapy suggest new avenues for its clinical application
Язык: Английский
Процитировано
0Medicinal Chemistry Research, Год журнала: 2025, Номер unknown
Опубликована: Март 31, 2025
Язык: Английский
Процитировано
0LWT, Год журнала: 2024, Номер unknown, С. 117191 - 117191
Опубликована: Дек. 1, 2024
Язык: Английский
Процитировано
1